ONCY
insider transactionsONCOLYTICS BIOTECH INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 10 different insiders made open-market purchases in the last 365 days, totalling $363.2K.
Net shares · 365d
+404.3K
404.3K buy · 0 sell
Net value · 365d
$363.2K
$363.2K in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
14
404.3K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
Transactions · 365d
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Chief Operating Officer
$0
145.0K sh
Own New
-
Grant·A
Look Kirk KEY
Chief Financial Officer
$0
260.0K sh
Own New
-
Grant·A
Kelly Jared KEY
Chief Executive Officer
$0
755.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
260.0K sh
Own New
-
Grant·A
Chief Technology Officer
$0
260.0K sh
Own New
-
Grant·A
Director
$0
96.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Chief Business Officer
$0
260.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Buy·P
Kelly Jared KEY
Chief Executive Officer
$4.8K
5.0K sh · $0.96
Own +5%
-
Buy·P
Director
$10.3K
10.0K sh · $1.03
Own +31%
-
Buy·P
Chief Medical Officer
$10.1K
12.1K sh · $0.83
Own +4%
-
Buy·P
Director
$25.2K
30.0K sh · $0.84
Own +6%
-
Buy·P
VP, Product Development
$8.3K
10.0K sh · $0.83
Own +10%
-
Buy·P
Director
$83.8K
100.0K sh · $0.84 avg · 2 lots
Own +21%
-
Buy·P
Kelly Jared KEY
Chief Executive Officer
$29.5K
35.1K sh · $0.84 avg · 2 lots
Own +47%
-
Buy·P
Director
$30.4K
35.4K sh · $0.86
Own +83%
-
Buy·P
Look Kirk KEY
Chief Financial Officer
$10.1K
12.0K sh · $0.84
Own +4%
-
Buy·P
Director
$21.2K
25.0K sh · $0.85
Own +29%
-
Buy·P
Chief Business Officer
$25.5K
29.6K sh · $0.86
Own +116%
-
Buy·P
Director
$104.0K
100.0K sh · $1.04
Own +27%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 1, 2026 | Jonathan Rigby | Grant A | 30.0K | $0 |
| Jun 1, 2026 | Pisano Wayne | Grant A | 30.0K | $0 |
| Jun 1, 2026 | Parsons James T. | Grant A | 30.0K | $0 |
| Jun 1, 2026 | Seizinger Bernd R. | Grant A | 30.0K | $0 |
| Jun 1, 2026 | John Bearden Mcadory | Grant A | 145.0K | $0 |
| Jun 1, 2026 | Look Kirk KEY | Grant A | 260.0K | $0 |
| Jun 1, 2026 | Kelly Jared KEY | Grant A | 755.0K | $0 |
| Jun 1, 2026 | Angela Holtham | Grant A | 30.0K | $0 |
| Jun 1, 2026 | Heineman Thomas Charles | Grant A | 260.0K | $0 |
| Jun 1, 2026 | Hagerman Allison | Grant A | 260.0K | $0 |
| Jun 1, 2026 | Glover Steve C | Grant A | 96.0K | $0 |
| Jun 1, 2026 | Brown Deborah Margaret | Grant A | 30.0K | $0 |
| Jun 1, 2026 | Aromando Andrew | Grant A | 260.0K | $0 |
| Jun 1, 2026 | Andrews Patricia S | Grant A | 30.0K | $0 |
| Mar 12, 2026 | Kelly Jared KEY | Buy P | 5.0K | $4.8K |
| Mar 11, 2026 | Parsons James T. | Buy P | 10.0K | $10.3K |
| Feb 12, 2026 | Heineman Thomas Charles | Buy P | 12.1K | $10.1K |
| Feb 12, 2026 | Pisano Wayne | Buy P | 30.0K | $25.2K |
| Feb 12, 2026 | Hagerman Allison | Buy P | 10.0K | $8.3K |
| Feb 12, 2026 | Seizinger Bernd R. | Buy P | 100.0K2 lots | $83.8K |
| Feb 12, 2026 | Kelly Jared KEY | Buy P | 35.1K2 lots | $29.5K |
| Feb 12, 2026 | Andrews Patricia S | Buy P | 35.4K | $30.4K |
| Feb 12, 2026 | Look Kirk KEY | Buy P | 12.0K | $10.1K |
| Feb 12, 2026 | Brown Deborah Margaret | Buy P | 25.0K | $21.2K |
| Feb 11, 2026 | Aromando Andrew | Buy P | 29.6K | $25.5K |
| Jan 16, 2026 | Seizinger Bernd R. | Buy P | 100.0K | $104.0K |
Buy Sell Non-market (grant · exercise · gift)
About ONCY insider trading
This page tracks insider transactions for ONCOLYTICS BIOTECH INC (ONCY) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.